Berlin Jordan D
Vanderbilt-Ingram Cancer Center, Vanderbilt University, Department of Medicine, Nashville, Tennessee, USA.
Oncology (Williston Park). 2007 May;21(6):712-8; discussion 720, 725-6, 730.
Despite attempted curative resection of localized adenocarcinoma of the pancreas, most patients experience a recurrence and die of their disease. The Gastrointestinal Tumor Study Group, European Organisation for Research and Treatment of Cancer, and European Study Group for Pancreatic Cancer trials have suggested the benefit of adjuvant therapy. However, the relatively few randomized trials available have not established a definite standard of care due to study limitations. Although these trials, and the recently published Chariti Onkologie (CONKO)-001 trial, have shown a definite advantage of adjuvant chemotherapy, the most effective chemotherapy and the role of radiation therapy remain unclear. This review will discuss the data available from reported trials of adjuvant and neoadjuvant therapy in pancreatic cancer, address the issues leading to the ongoing controversies, and consider future directions for clinical trials.
尽管尝试对局限性胰腺腺癌进行根治性切除，但大多数患者仍会复发并死于该疾病。胃肠道肿瘤研究组、欧洲癌症研究与治疗组织以及欧洲胰腺癌研究组的试验均表明辅助治疗有益。然而，由于研究局限性，现有的相对较少的随机试验尚未确立明确的治疗标准。尽管这些试验以及最近发表的Chariti Onkologie（CONKO）-001试验已显示辅助化疗具有明确优势，但最有效的化疗方法以及放射治疗的作用仍不明确。本综述将讨论胰腺癌辅助和新辅助治疗报告试验中的现有数据，解决导致持续争议的问题，并考虑临床试验的未来方向。
